Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD reports positive Cordaptive trial results

MSD reports positive Cordaptive trial results

4th September 2007

Merck, Sharp and Dohme (MSD) has announced positive phase III clinical trial results of Cordaptive (ER niacin/laropiprant), with the compound reducing LDL-cholesterol and triglyceride levels and increasing HDL-cholesterol when compared to placebo.

Cordaptive is an investigational orally-administered compound containing extended-release formulation of niacin and innovative flushing pathway inhibitor laropiprant.

According to the trial results, presented this week at the European Society of Cardiology congress in Vienna, patients administered with the compound exhibited less flushing than those treated solely with niacin.

Anders Olsson, professor at the Faculty of Health Sciences of Linkoping University in Sweden, commented that some drugs that lower LDL-cholesterol reduce the risk of heart attack and stroke, but leave patients at risk of cardiovascular events.

“Niacin has been shown in previous outcome studies to reduce the risk of cardiovascular events, but its use has been limited as a result of the flushing side effect,” he said.

He added that the results of this phase III study suggest that patients may be less like to discontinue their treatment as a result of flushing.

In November 2006, MSD presented clinical trial data to the scientific sessions of the American Heart Association claiming that the compound significantly reduced flushing compared to the sole use of extended-release niacin.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.